^
Association details:
| Biomarker: | ROS1 rearrangement |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
Excerpt:
...- Histologically or cytologically confirmed diagnosis of stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement (cohort 1) or MET-activating mutation (exon 14) (cohort 2) or MET-amplification (cohort 3) tested in either plasma or tissue, as applicable...
Trial ID:
Source:
Title:
Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
Published date:
10/22/2021
Excerpt:
We enrolled 95 non-squamous NSCLC patients with known status of EGFR, ALK, ROS1, MET and RET genes and PD-L1 protein expression….In 32 patients with ALK or ROS1 genes rearrangements, 10 patients received crizotinib and 22 patients chemotherapy in the first-line of treatment. The median overall survival was 34 months (95% CI 9.5–34 months) in crizotinib treated patients and 6 months (95% CI 4–15.5 months) in patients who received chemotherapy (HR = 0.266, 95% CI 0.104–0.678, p = 0.0056)...
DOI:
https://doi.org/10.1038/s41598-021-00309-3
